179 related articles for article (PubMed ID: 21886838)
1. Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.
Basu A; Banerjee P; Contreras AG; Flynn E; Pal S
PLoS One; 2011; 6(8):e23919. PubMed ID: 21886838
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells.
Datta D; Contreras AG; Basu A; Dormond O; Flynn E; Briscoe DM; Pal S
Cancer Res; 2009 Dec; 69(23):8902-9. PubMed ID: 19903851
[TBL] [Abstract][Full Text] [Related]
3. Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development.
Basu A; Datta D; Zurakowski D; Pal S
J Biol Chem; 2010 Aug; 285(33):25196-202. PubMed ID: 20554520
[TBL] [Abstract][Full Text] [Related]
4. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression.
Basu A; Liu T; Banerjee P; Flynn E; Zurakowski D; Datta D; Viklicky O; Gasser M; Waaga-Gasser AM; Yang J; Pal S
Cancer Lett; 2012 Aug; 321(2):179-86. PubMed ID: 22343319
[TBL] [Abstract][Full Text] [Related]
6. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
Dormond O; Contreras AG; Meijer E; Datta D; Flynn E; Pal S; Briscoe DM
J Immunol; 2008 Dec; 181(11):8088-95. PubMed ID: 19018001
[TBL] [Abstract][Full Text] [Related]
7. The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways.
Banerjee P; Basu A; Arbiser JL; Pal S
Cancer Lett; 2013 Sep; 338(2):292-9. PubMed ID: 23752066
[TBL] [Abstract][Full Text] [Related]
8. Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.
Balan M; Chakraborty S; Flynn E; Zurakowski D; Pal S
Sci Rep; 2017 Jul; 7(1):5900. PubMed ID: 28724911
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of insulin-stimulated 4E-BP protein binding to mammalian target of rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1 signaling.
Rapley J; Oshiro N; Ortiz-Vega S; Avruch J
J Biol Chem; 2011 Nov; 286(44):38043-38053. PubMed ID: 21914810
[TBL] [Abstract][Full Text] [Related]
10. PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Dougherty MI; Lehman CE; Spencer A; Mendez RE; David AP; Taniguchi LE; Wulfkuhle J; Petricoin EF; Gioeli D; Jameson MJ
Mol Cancer Res; 2020 Sep; 18(9):1392-1401. PubMed ID: 32467173
[TBL] [Abstract][Full Text] [Related]
11. Stretch-induced retinal vascular endothelial growth factor expression is mediated by phosphatidylinositol 3-kinase and protein kinase C (PKC)-zeta but not by stretch-induced ERK1/2, Akt, Ras, or classical/novel PKC pathways.
Suzuma I; Suzuma K; Ueki K; Hata Y; Feener EP; King GL; Aiello LP
J Biol Chem; 2002 Jan; 277(2):1047-57. PubMed ID: 11694503
[TBL] [Abstract][Full Text] [Related]
12. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1.
Oshiro N; Takahashi R; Yoshino K; Tanimura K; Nakashima A; Eguchi S; Miyamoto T; Hara K; Takehana K; Avruch J; Kikkawa U; Yonezawa K
J Biol Chem; 2007 Jul; 282(28):20329-39. PubMed ID: 17517883
[TBL] [Abstract][Full Text] [Related]
13. Alcohol and PRAS40 knockdown decrease mTOR activity and protein synthesis via AMPK signaling and changes in mTORC1 interaction.
Hong-Brown LQ; Brown CR; Kazi AA; Huber DS; Pruznak AM; Lang CH
J Cell Biochem; 2010 Apr; 109(6):1172-84. PubMed ID: 20127721
[TBL] [Abstract][Full Text] [Related]
14. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
15. The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal.
Banerjee P; Basu A; Datta D; Gasser M; Waaga-Gasser AM; Pal S
J Biol Chem; 2011 Sep; 286(38):33580-90. PubMed ID: 21808062
[TBL] [Abstract][Full Text] [Related]
16. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding.
Wang L; Harris TE; Roth RA; Lawrence JC
J Biol Chem; 2007 Jul; 282(27):20036-44. PubMed ID: 17510057
[TBL] [Abstract][Full Text] [Related]
17. Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation.
Wang L; Harris TE; Lawrence JC
J Biol Chem; 2008 Jun; 283(23):15619-27. PubMed ID: 18372248
[TBL] [Abstract][Full Text] [Related]
18. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.
Khan N; Afaq F; Khusro FH; Mustafa Adhami V; Suh Y; Mukhtar H
Int J Cancer; 2012 Apr; 130(7):1695-705. PubMed ID: 21618507
[TBL] [Abstract][Full Text] [Related]
20. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells.
Zhang F; Beharry ZM; Harris TE; Lilly MB; Smith CD; Mahajan S; Kraft AS
Cancer Biol Ther; 2009 May; 8(9):846-53. PubMed ID: 19276681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
